Geron Corp
GERN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.12
KIRA · Stoqly’s AI analyst, in plain words
- Geron Corp lost $83.5M in fiscal 2025.
- Geron Corp owes $42.0M more than it holds in cash.
Market cap
$0.8M
P/E
—
Revenue
—
Net income
−$83.5M
Free cash flow
—
Operating margin
—
Geron Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$83.5M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Geron Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- GERON CORP
- CIK
- 0000886744
Geron Corp · GERN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.4M | $0.6M | $0.2M | — | — |
| Revenue growth | 450.6% | −57.2% | −60.2% | — | — |
| Operating margin | −8,183.7% | −23,246.6% | −81,832.9% | — | — |
| Net income | −$116M | −$142M | −$184M | −$175M | −$83.5M |
| Net margin | −8,335.4% | −23,808.9% | −77,690.7% | — | — |
| Diluted EPS | −$0.35 | −$0.37 | −$0.32 | −$0.27 | −$0.13 |
| Cash | |||||
| Cash from operations | −$95.6M | −$127M | −$168M | −$219M | −$111M |
| Capital expenditure | $0.2M | $0.4M | $0.8M | $0.7M | — |
| Free cash flow | −$95.8M | −$128M | −$169M | −$219M | — |
| FCF margin | −6,874.6% | −21,444.6% | −71,127.8% | — | — |
| Share count change | 20.7% | 16.2% | 49.9% | 13.2% | 3.2% |
| Debt and strength | |||||
| Cash and short-term investments | $184M | $173M | $334M | $407M | $77.6M |
| Debt incl. finance leases | $49.8M | $72.1M | $129M | $118M | $120M |
| Shareholders' equity | $126M | $80.0M | $248M | $280M | $226M |
| Current ratio | 4.1x | 2.4x | 3.2x | 5.6x | 4.7x |
| Interest coverage | −30.5x | −20.1x | −23.3x | −9.4x | −2.1x |
| Returns and quality | |||||
| Return on capital | — | — | −355.6% | — | −20.2% |
| Return on equity | −68.8% | −137.5% | −112.3% | −66.1% | −33.0% |
| Return on tangible equity | −91.8% | −177.4% | −74.3% | −62.3% | −37.0% |
| Piotroski F-score | 2 | 1 | 4 | 3 | 1 |
| Altman Z'' | −16.3 | −24.7 | −10.9 | −6.3 | −6.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Geron Corp · GERN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.12 a share, the company is worth $0.8M.
Source: SEC EDGAR XBRL filings (CIK 0000886744). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.